Garuda Therapeutics

Overview

Located in Massachusetts, this biotechnology company specializes in developing off-the-shelf hematopoietic stem cell therapies that eliminate the need for donor or patient cells in blood stem cell transplants. Their proprietary platform produces self-renewing, HLA-compatible, and transgene-free blood stem cells that are available immediately to patients, offering curative treatments for over 120 diseases including blood disorders, cancers, autoimmune diseases, and rare hematologic conditions.

Focused on building a future free from donor reliance for transplants, the company has recently raised $50 million in Series A-1 financing to accelerate growth, clinical development, and manufacturing. Their therapies are designed for broad accessibility, minimizing rejection risk and complications from genetic modification, and aim to address critical needs across regenerative medicine and hematology.

Basic Information

Contact Details

• Phone: +1 617-851-4586
• Website: garudatx.com
• LinkedIn: linkedin.com/company/garuda-therapeutics

Key Focus Areas & Initiatives

• Off-the-shelf hematopoietic stem cell therapies
• Donor-independent stem cell transplants
• Self-renewing, HLA-compatible, transgene-free blood stem cells
• Curative treatments for blood disorders, cancers, autoimmune diseases, and rare conditions
• Reducing risk of rejection and genetic modification complications
• Broad disease applicability in regenerative medicine
• Clinical development and manufacturing scale-up
• Next-generation and immune-compatible cell therapies
• Biotech innovation and platform development
• Venture-backed clinical trials and biotech investment

Technologies Used

• Microsoft Office 365
• Outlook
• Remote